Platelets in the Alzheimer's disease brain: Do they play a role in cerebral amyloid angiopathy?

Current Neurovascular Research

Volumn 12, Issue 1, 2015, Pages 4-14

  Kniewallner, Kathrin M ^a   Ehrlich, Daniela ^a   Kiefer, Andreas ^b   Marksteiner, Josef ^c   Humpel, Christian ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b GENERAL HOSPITAL KLAGENFURT   (Austria)

^c Psychiatr Landeskrankenhaus Hall Tirol   (Austria)

Author keywords

Alzheimer; Migration; Platelet; Postmortem; Vessel

Indexed keywords

FIBRINOGEN RECEPTOR; PADGEM PROTEIN; AMYLOID PRECURSOR PROTEIN; CDKN1A PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; GLYCOPROTEIN IIB; ORGANIC COMPOUND; PKH 26;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; BLOOD VESSEL WALL; BRAIN; BRAIN BLOOD VESSEL; CELL MIGRATION; CONTROLLED STUDY; FLUORESCENCE; IMMUNOHISTOCHEMISTRY; LIVER; LUNG; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE; VASCULAR AMYLOIDOSIS; ADULT; AGED; ANIMAL; C57BL MOUSE; CEREBRAL AMYLOID ANGIOPATHY; DISEASE MODEL; FEMALE; FLOW CYTOMETRY; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BLOOD PLATELETS; BRAIN; CEREBRAL AMYLOID ANGIOPATHY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; ORGANIC CHEMICALS; P-SELECTIN; PLATELET MEMBRANE GLYCOPROTEIN IIB;

EID: 84924704970     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/1567202612666150102124703     Document Type: Article

References (59)

1. Horstman LL, Jy W, Ahn YS, et al. Role of platelets in neuroinflammation: a wide-angle perspective. J Neuroinfallmation 2010; 3; 7: 10.
2. Humpel C. Chronic mild cerebrovascular dysfunction as a cause for Alzheimers disease? Exp Gerontol 2011; 46 (4): 225-32.
3. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004; 5 (5): 347-360.
4. De la Torre J.C. Alzheimer's disease as a vascular disorder. Stroke 2000; 33: 1152-1162.
5. Casoli T, Balietti M, Giorgetti B, Solazzi M, Scarpino O, Fattoretti P. Platelets in Alzheimer's disease-associated cellular senescence and inflammation. Curr Pharm Des. 2013; 19 (9): 1727-38
6. Randriamboavonjy V, Sopova K, Stellos K, Laske C. Platelets as potential link between diabetes and Alzheimer's disease. Curr Alzheimer Res 2014; 11 (9): 862-8.
7. Zhang W, Huang W, Jing F. Contribution of blood platelets to vascular pathology in Alzheimer's disease. J Blood Med 2013; 4: 141-7.
8. Jarre A, Gowert NS, Donner L, et al. Pre-activated blood platelets and a pro-thrombotic phenotype in APP23 mice modeling Alzheimer's disease. Cell Signal 2014; 26 (9): 2040-50.
9. Jellinger KA. Alzheimers disease and cerebrovascular pathology: an update. J Neural Transm 2002; 109 (5-6): 813-836.
10. Langer HF, Chavakis T. Platelets and neurovascular inflammation. Thromb Haemost. 2013; 110 (5): 888-93.
11. Gowert NS, Donner L, Chatterjee M, et al. Blood platelets in the progression of Alzheimer's disease. PLoS One 2014; 9 (2): e90523.
12. Milovanovic M, Eriksson K, Winblad B, et al. Alzheimer and platelets: low-density platelet populations reveal increased serotonin content in Alzheimer type dementia. Clin biochem 2014; 47 (15): 51-3.
13. Evin G, Zhu A, Holsinger RM, Masters CL, Li QX. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets. Neurosci Res 2003; 74 (3): 386-92.
14. Sevush S, Jy W, Horstman LL, Mao WW, Kolodny L, Ahn YS. Platelet activation in Alzheimer disease. Arch Neurol 1998; 55 (4): 530-6.
15. Zubenko GS, Cohen BM, Reynolds CF 3rd, Boller F, Teply I, Chojnacki B. Platelet membrane fluidity identifies a clinical subtype of Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1987; 11 (6): 683-99.
16. Vignini A, Giusti L, Raffaeli F, et al. Impact of gender on platelet membrane functions of Alzheimer's disease patients. Exp Gerontol 2013; 48 (3): 319-25.
17. Di Luca M, Pastorino L, Cattabeni F, et al. Abnormal pattern of platelet APP isoforms in Alzheimer disease and Down syndrome. Arch Neurol 1996; 53 (11): 1162-6.
18. Di Luca M, Pastorino L, Bianchetti A, et al. Differential level of platelet amyloid beta precursor protein isoforms: an early marker for Alzheimer disease. Arch Neurol 1998; 55 (9): 1195-200.
19. Rakesh KS, Jagadish S, Vinayaka AC, et al. A new ibuprofen derivative inhibits platelet aggregation and ROS mediated platelet apoptosis. PLoS One. 2014; 9 (9): e107182.
20. Zassler B, Humpel C. Transplantation of NGF secreting primary monocytes counteracts NMDA-induced cell death of rat cholinergic neurons in vivo. Exp Neurol 2006; 198 (2): 391-400.
21. Kniewallner KM, Grimm N, Humpel C. Platelet-derived nerve growth factor supports the survival of cholinergic neurons in organotypic rat brain slices, Neurosci Lett 2014; 574: 64-9.
22. Davis J, Xu F, Deane R, et al. Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J Biol Chem. 2004; 279 (19): 20296-306.
23. Metzelaar MJ, Korteweg J, Sixma JJ, Nieuwenhuis HK. Biochemical characterization of PECAM-1 (CD31 antigen) on human platelets. Thromb Haemost 1991; 66 (6): 700-7.
24. Jiménez-Marín A, Yubero N, Esteso G, et al. Molecular characterization and expression analysis of the gene coding for the porcine beta (3) integrin subunit (CD61). Gene 2008; 408 (1-2): 9-17.
25. Ishida K, Taguchi K, Matsumoto T, Kobayashi T. Activated platelets from diabetic rats cause endothelial dysfunction by decreasing Akt/endothelial NO synthase signaling pathway. Plos One 2014; 9 (7): e102310.
26. Junt T, Schulze H, Chen Z, et al. Dynamic visualization of thrombopoiesis within bone marrow. Science 2007; 317 (5845): 1767-70.
27. Wekerle H, Linington C, Lassmann H, Meyermann R. Cellular immune reactivity within the CNS. Trends in Neurosciences 1986; 9: 271-277.
28. Wekerle H. [The enigma of arrival: [corrected] the entrance of auto-immune T lymphocytes in central nervous tissues and of their attack against the myelin structures]. C R Biol 2007; 330 (1): 1-12.
29. Lampron, A., Pimentel-Coelho, P.M., Rivest, S. Migration of bone marrow-derived cells into the central nervous system in models of neurodegeneration. J Comparative Neurol 2013; 521 (17): 3863-3876.
30. Shi, C., Pamer, E.G. Monocyte recruitment during infection and inflammation. Nat Rev Immunol 2011; 11: 762-774.
31. Togo, T., Akiyama, H., Iseki, E., et al. Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. J Neuroimmunol 2002; 124 (1-2): 83-92.
32. Hickey WF, Hsu BL, Kimura. T-lymphocyte entry into the central nervous system. J Neurosci Res 1991; 28 (2): 254-260.
33. Lebson L, Nash K, Kamath S, et al. Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloiddepositing transgenic mice. J Neurosci 2010; 30 (29): 9651-8.
34. Hawkes CA, McLaurin J. Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc Natl Acad Sci USA 2009; 106 (4): 1261-6.
35. Mildner A, Schlevogt B, Kierdorf K, et al. Distinct and nonredundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. J Neurosci 2011; 31 (31): 11159-71.
36. Michaud JP, Bellavance MA, Préfontaine P, Rivest S. Real-time in vivo imaging reveals the ability of monocytes to clear vascular amyloid beta. Cell 2013; 5 (3): 646-53.
37. Fiala M, Zhang L, Gan X, et al. Amyloid-beta induces chemokine secretion and monocyte migration across a human blood-brain barrier model. Mol Med 1998; 4 (7): 480-9.
38. Tian L, Zhang K, Tian ZY, et al. Decreased Expression of Cathepsin D in Monocytes is Related to the Defective Degradation of Amyloid-β in Alzheimer's Disease. J Alzheimers Dis 2014; 42 (2): 511-20.
39. van Gils JM, Zwaginga JJ, Hordijk PL. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J Leukoc Biol 2009; 85 (2): 195-204.
40. von Hundelshausen, P., Koenen, R.R., Weber, C. Platelet-mediated enhancement of leukocyte adhesion. Microcirculation 2009; 16 (1): 84-96.
41. Hanyu H, Tanaka Yu, Shimizu S, Takasaki M, Abe K. Cerebral microbleeds in Alzheimer's disease. J Neurol 2003; 250 (12): 1496-7.
42. Goos JD, Kester MI, Barkhof F, et al. Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition. Stroke 2009; 40 (11): 3455-60.
43. Cordonnier C, van der Flier WM, Sluimer JD, Leys D, Barkhof F, Scheltens P. Prevalence and severity of microbleeds in a memory clinic setting. Neurology 2006; 66 (9): 1356-60.
44. Nakata-Kudo Y, Mizuno T, Yamada K, et al. Microbleeds in Alzheimer disease are more related to cerebral amyloid angiopathy than cerebrovascular disease. Dement Geriatr Cogn Disord 2006; 22 (1): 8-14
45. Pettersen JA, Sathiyamoorthy G, Gao FQ, et al. Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook dementia study. Arch Neurol 2008; 65 (6): 790-5.
46. Lee CW, Shih YH, Kuo YM. Cerebrovascular pathology and amyloid plaque formation in Alzheimer's disease. Curr Alzheimer Res 2014; 11 (1): 4-10.
47. Gurol ME, Greenberg SM. A physiologic biomarker for cerebral amyloid angiopathy. http://www.ncbi.nlm.nih.gov/pubmed/24097811 Neurology 2013; 81 (19): 1650-1.
48. Thal DR, Ghebremedhin E, Orantes M, Wiestler OD. Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. J Neuropathol Exp Neurol 2003; 62 (12): 1287-30.
49. Werring DJ, Gregoire SM, Cipolotti L. Cerebral microbleeds and vascular cognitive impairment, J Neurol Sci 2010; 299 (1-2): 131-5.
50. Heringa SM, Reijmer YD, Leemans A, Koek HL, Kappelle LJ, Biessels GJ; Utrecht Vascular Cognitive Impairment (VCI) Study Group. Multiple microbleeds are related to cerebral network disruptions in patients with early Alzheimer's disease. J Alzheimers Dis 2014; 38 (1): 211-21.
51. Provias J, Jeynes B. Neurofibrillary tangles and senile plaques in Alzheimer's brains are associated with reduced capillary expression of vascular endothelial growth factor and endothelial nitric oxide synthase. Curr Neurovasc Res 2008; 5 (3): 199-205.
52. Garcia JH, Brown GG. Vascular dementia: neuropathologic alterations and metabolic brain changes. J Neurol Sci 1992; 109 (2): 121-3.
53. Munoz DG. The pathological basis of multi-infarct dementia. Alzheimer Dis Assoc Disord 1991; 5 (2): 77-90.
54. Olsson Y, Brun A, Englund E. Fundamental pathological lesions in vascular dementia. Acta Neurol Scand Suppl 1996; 168: 31-8.
55. Breteler MM. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 2000; 21 (2): 153-60.
56. Ehrlich D, Humpel C. Chronic vascular risk factors (cholesterol, homocysteine, ethanol) impair spatial memory, decline cholinergic neurons and induce blood-brain barrier leakage in rats in vivo. J Neurol Sci 2012; 322 (1-2): 92-5.
57. Borroni B, Archetti S, Ferrari M, Cesana BM, Padovani A. Relationship of vascular risk to the progression of Alzheimer disease. Neurology 2007; 68 (13): 1083-1084.
58. Stokes KY, Granger DN. Platelets: a critical link between inflammation and microvascular dysfunction. J Physiol 2012; 590 (5): 1023-34.
59. Veitinger M, Oehler R, Umlauf E, et al. A platelet protein biochip rapidly detects an Alzheimer's disease-specific phenotype. Acta Neuropathol. 2014; 128 (5): 665-77.